Vertex investors have lately shifted their focus from the company's flagship cystic fibrosis franchise to the nonopioid pain med candidate suzetrigine. (Joseph Prezioso/AFP/Getty Images) As Vertex ...
Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The last time I spoke about Vertex Pharmaceuticals (VRTX) it was with a Seeking Alpha article entitled "Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant ...
TRIKAFTA is Vertex Pharma’s flagship triple-combination cystic fibrosis therapy, approved in the US for patients as young as 2 years with at least one F508del mutation, and remains the company’s key ...
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results